DHPG and Interferon Beta Combination for Cytomegalovirus Retinitis Relapse Prevention in AIDS Patients

This study focuses on preventing the recurrence of cytomegalovirus retinitis, an eye infection caused by the cytomegalovirus, in individuals living with AIDS. The study combines two medications, ganciclovir (DHPG) and interferon beta, to achieve this goal. While DHPG is typically effective, it can lead to a common side effect called neutropenia, a decrease in white blood cells, in about half of the patients. Research suggests that combining DHPG with interferon beta may enhance their effectiveness against cytomegalovirus. This could allow for lower doses of DHPG, potentially reducing the risk of neutropenia. The study aims to improve care for patients with AIDS by finding a safer and more effective treatment approach for cytomegalovirus retinitis. During the study, participants receive a combination of DHPG and interferon beta. The dose of DHPG is lower than usual, while interferon beta is given in a low dose. The goal is to prevent the relapse of the eye infection without causing neutropenia. The effectiveness of this treatment approach is evaluated by monitoring the participants for any signs of infection recurrence and changes in their white blood cell counts. If the combination therapy successfully maintains remission, a subsequent phase of the study will assess maintenance therapy using a moderate dose of interferon beta alone.